BNP Paribas Financial Markets
BCLI

BNP Paribas Financial Markets’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

BNP Paribas Financial Markets’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24
Closed -$27 – 5565
2025
Q2 		$27 Hold
24
– – ﹤0.01% 5381
2025
Q1 		$30 Hold
24
– – ﹤0.01% 5308
2024
Q4 		$54 Buy
+24
New +$44 ﹤0.01% 5314
2024
Q3 		– Sell
-24
Closed -$123 – 4143
2024
Q2 		$123 Hold
24
– – ﹤0.01% 3958
2024
Q1 		$206 Hold
24
– – ﹤0.01% 3945
2023
Q4 		$99 Hold
24
– – ﹤0.01% 3953
2023
Q3 		$73 Hold
24
– – ﹤0.01% 3861
2023
Q2 		$750 Hold
24
– – ﹤0.01% 3781
2023
Q1 		$1.2K Hold
24
– – ﹤0.01% 3670
2022
Q4 		$597 Hold
24
– – ﹤0.01% 3849
2022
Q3 		$1.61K Hold
24
– – ﹤0.01% 4366
2022
Q2 		$1K Sell
24
-8
-25% -$360 ﹤0.01% 3908
2022
Q1 		$1.62K Hold
32
– – ﹤0.01% 3928
2021
Q4 		$1.92K Hold
32
– – ﹤0.01% 3996
2021
Q3 		$1.59K Sell
32
-95
-75% -$5K ﹤0.01% 3828
2021
Q2 		$7.23K Sell
127
-145
-53% -$7.75K ﹤0.01% 3779
2021
Q1 		$15.6K Sell
272
-136
-33% -$10.3K ﹤0.01% 3793
2020
Q4 		$27.7K Sell
408
-38
-9% -$5.17K ﹤0.01% 3775
2020
Q3 		$113K Buy
446
+379
+566% +$77.6K ﹤0.01% 3052
2020
Q2 		$11.2K Buy
+67
New +$7.22K ﹤0.01% 3656

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

BNP Paribas Financial Markets's BCLI Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 24 shares — an estimated $27 sold.

BNP Paribas Financial Markets first reported a position in BCLI in Q2 2020 and held it in 20 quarters. The position peaked at $113K in Q3 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • BNP Paribas Financial Markets reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 24 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $27.
  • BNP Paribas Financial Markets first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 20 quarters.
  • BNP Paribas Financial Markets's BRAINSTORM CELL THERAPUTC position peaked at $113K in Q3 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.